← All trials
NCT03994783
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Oct 31, 2026
- Completion date
- Jul 31, 2027
- First posted
- —
- Last posted
- —
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Imperial College LondonLead sponsor
- National Institute for Health Research, United KingdomCollaborator
- Kidney Cancer UKCollaborator
- Imperial College LondonOverall official - principal investigator
- University of CambridgeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.